文献速递临床微生物分子诊断

Deeplex Myc-TB靶向二代测序评估:分枝杆菌鉴定与耐药检测

Evaluation of the deeplex Myc-TB-targeted next-generation sequencing assay for mycobacterial identification and drug resistance detection.
PubMed 文献 · J Clin Microbiol · 2026-05-29

该研究在304例培养阳性MGIT肉汤中评估Deeplex Myc-TB靶向测序,273例获确定性结果,MTBC鉴定与GeneXpert完全一致,NTM鉴定与MALDI-TOF MS符合率98.8%。18例无耐药突变MTBC与表型药敏100%一致,11例携带至少一个耐药突变,其中1例符合耐多药结核标准。

要点

  • Deeplex Myc-TB可同时鉴定MTBC/NTM并检测耐药突变,MTBC鉴定与GeneXpert 100%一致。
  • 18例无耐药突变MTBC与表型药敏100%一致,支持基因型预测易感性的可靠性。
  • NTM鉴定与MALDI-TOF MS确认一致,并可分辨MAC和M. abscessus亚种。

核心结论

  • Deeplex Myc-TB对MTBC耐药谱高分辨率分析和NTM种及亚种精准鉴定具有较强诊断潜力。

研究设计与样本

  • 在2024年5月至2025年3月收集的304例原代培养阳性MGIT肉汤上评估Deeplex Myc-TB。
  • MTBC鉴定采用GeneXpert MTB/RIF,表型药敏采用Sensititre MYCOTB肉汤微量稀释法或MGIT panel。

主要发现

  • 273株获确定性结果,包括29株MTBC和244株NTM,MTBC鉴定一致率100%,NTM一致率98.8%。
  • 29株MTBC中18株(62.1%)未检出耐药突变,表型药敏确认全部受试药物敏感,与Deeplex预测敏感100%一致。
  • 其余11株(37.9%)携带至少一个耐药突变,其中7株携带经典耐药突变,1株符合耐多药结核标准。
  • 244株NTM均有MALDI-TOF MS鉴定,Deeplex确认并提供了MAC和M. abscessus亚种水平分辨。

关键数值与推荐

  • MTBC鉴定一致率100%(29株),NTM鉴定一致率98.8%(244株)。
  • 无耐药突变MTBC(18株)Deeplex预测敏感与表型药敏100%一致。
  • 携带经典耐药突变且有CLSI折点的菌株,基因型与表型药敏一致;1株符合耐多药结核标准。

临床怎么用

  • 可将靶向测序整合入常规工作流程,单次检测同时获得菌种鉴定和耐药信息以优化早期治疗。
  • 对NTM可提供亚种水平分辨,有助于临床重要菌群如MAC和M. abscessus的精准识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accurate differentiation of Mycobacterium tuberculosis complex (MTBC) and nontuberculous mycobacteria (NTM), together with early detection of drug resistance, is essential for guiding therapy and infection control. Targeted next-generation sequencing assays, such as the Deeplex Myc-TB (GenoScreen, Lille, France), allow simultaneous identification of species and detection of drug-resistance mutations. We evaluated Deeplex Myc-TB on 304 primary, culture-positive mycobacterial growth indicator tube (MGIT) broths collected between May 2024 and March 2025. The assay generated determinate results for 273 isolates, comprising 29 MTBC and 244 NTM, with 100% agreement for MTBC identification, and 98.8% for NTM. MTBC identification was performed using GeneXpert MTB/RIF, whereas phenotypic drug susceptibility testing (pDST) was performed using either the Sensititre MYCOTB broth microdilution method, or the MGIT-based panel. Among the 29 unique MTBC isolates, 18 (62.1%) had no detectable drug-resistance mutations (DRMs). Phenotypic drug susceptibility testing confirmed susceptibility to all tested drugs for these 18 isolates, resulting in 100% concordance with Deeplex-predicted susceptibility, and no evidence of heteroresistance. The remaining 11 isolates (37.9%) carried at least one DRM, including seven with canonical resistance-conferring mutations. For isolates with canonical DRMs and available CLSI breakpoints, genotypic calls and pDST were concordant, and one isolate met the criteria for multidrug-resistant tuberculosis. All 244 NTM isolates had prior matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) identification; Deeplex confirmed these identifications and provided subspecies-level resolution within the Mycobacterium avium complex and Mycobacterium abscessus. These findings demonstrate the strong diagnostic potential of Deeplex Myc-TB for high-resolution MTBC resistance profiling and precise NTM species and subspecies identification. Integrating targeted sequencing into routine workflows can improve clinical decision-making, support early treatment optimization, and strengthen molecular surveillance of mycobacterial diseases.IMPORTANCERapid and accurate identification of mycobacteria and detection of drug resistance are essential for timely patient management and public health control of tuberculosis and nontuberculous mycobacterial infections. However, routine diagnostics often rely on multiple sequential assays, which can delay comprehensive results. In this study, we demonstrate that targeted next-generation sequencing using Deeplex Myc-TB can provide high-resolution species identification and clinically meaningful drug-resistance information in a single workflow within a U.S. clinical laboratory setting. The assay showed complete concordance with GeneXpert MTB/RIF for identification of the Mycobacterium tuberculosis complex and produced genotypic resistance predictions consistent with phenotypic drug susceptibility testing, where interpretive criteria were available. For nontuberculous mycobacteria, the assay confirmed MALDI-TOF MS identifications and enabled subspecies-level discrimination within clinically important groups, including the Mycobacterium avium complex and Mycobacterium abscessus. These findings support the integration of targeted sequencing into routine mycobacterial diagnostics to streamline laboratory workflows, improve the timeliness and clinical relevance of reporting, and enhance molecular surveillance efforts.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Notarte KI, Allen K, Armstrong DT, et al. Evaluation of the deeplex Myc-TB-targeted next-generation sequencing assay for mycobacterial identification and drug resistance detection. J Clin Microbiol. 2026. PMID: 42214384. doi:10.1128/jcm.00082-26

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。